Successful Helicobacter pylori eradication therapy improves symptoms of chronic constipation. Issue 6 (15th October 2018)

• Record Type: Journal Article
• Authors: Murata, Masaki; Sugimoto, Mitsushige; Otsuka, Taketo; Nishida, Atsushi; Inatomi, Osamu; Bamba, Shigeki; Andoh, Akira
• Is Part Of: Helicobacter. Volume 23:Issue 6(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-10-15
• Subjects: Constipation/MI -- defecation -- Helicobacter pylori/PY -- microbiota; Helicobacter -- Periodicals; Helicobacter infections -- Periodicals; Stomach -- Diseases -- Periodicals; 616.3301405
• DOI: 10.1111/hel.12543
• Languages: English
• ISSNs: 1083-4389

Abstract

Abstract: Backgrounds and Aims: Constipation is one of the most common gastrointestinal functional disorders. Recently, the gut microbiota has been implicated in the development of constipation. Helicobacter pylori infection is considered to be a possible factor influencing the gut microbiota profile. Here, we investigated the effect of H. pylori eradication therapy on symptoms of chronic constipation. Methods: We recruited 166 H pylori ‐positive patients who underwent eradication therapy after endoscopy. We evaluated the severity of symptoms of chronic constipation before eradication therapy and 2 months post‐therapy using two questionnaires, the Gastrointestinal Symptom Rating Scale (GSRS) and the Izumo scale. In addition, we evaluated association with constipation and H. pylori infection in patients with constipation‐related symptoms in not only all patients, but also patients with the constipation‐related symptoms in relation to eradication outcome, the severity of constipation‐related symptoms, and the severity of endoscopic gastric mucosal atrophy. Results: Mean GSRS scores were 5.10 ± 2.67 in all patients and 6.15 ± 2.91 in constipation patients which were significantly lower than that before eradication (5.78 ± 3.27, P < 0.01 and 8.19 ± 3.09, P < 0.01, respectively). Constipation‐related scores of the GSRS questionnaire in the successful eradication group were significantly improved after eradication from 5.63 ± 3.06 in all patients and 8.00 ± 2.85 in constipation patients to 5.11 ± 2.71 ( P = 0.02) and 6.16 ± 2.96 ( P < 0.01), while scores in the failed eradication group before and after eradication were similar. Constipation‐related scores in patients with mild gastric atrophy (Kimura‐Takemoto classification, C‐I to O‐I) were significantly decreased after eradication, but were not decreased in patients with severe atrophy (O‐II and O‐III). Conclusions: Successful eradication therapy for H. pylori infection may confer additional benefits in H. pylori‐ positive patients with symptoms of chronic constipation, especially in patients with mild gastric atrophy.